Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Monday, November 4, 2024
A study published in Scientific Reports examined the influence of family tumor history on treatment response, tumor metabolism, and disease-free survival in patients with non–small cell lung cancer (NSCLC). Kai Zheng, MD, of Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, and colleagues used fluorine-18 (F-18) fluorodeoxyglucose PET/CT to assess tumor glucose metabolism and multivariate modeling analyses to improve prognostic prediction. Their findings revealed that patients with a family cancer history exhibited higher tumor staging, increased susceptibility to lymph node invasion, and elevated tumor glucose metabolism levels.
“NSCLC… is a leading cause of cancer-related mortality, and the role of family cancer history in disease progression and treatment response remains underexplored… Our study highlights the importance of considering a patient’s family history when assessing risk profiles and formulating treatment decisions for NSCLC patients,” stated Dr. Zheng and colleagues.
A total of 414 patients with NSCLC were included in this retrospective, single-center study. Of them, a total of 101 had a family history of cancer. Analyses were conducted to assess disease-free survival; tumor glucose metabolism; and treatment responses following chemotherapy, targeted therapy, and immunotherapy. Additionally, multivariate models were used to improve the prognostic prediction of analyses.
Findings revealed that patients with a family history of cancer exhibited higher TNM staging. Specifically, a family history of colorectal and lung cancers was a significant risk factor for disease-free survival. Increased susceptibility to lymph node invasion and elevated tumor glucose metabolism levels were also observed in patients with a family history of cancer. Although improved prognosis was found in patients who received targeted therapy and immunotherapy, those with a family history of cancer had reduced efficacy of chemoradiotherapy.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
